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Abstract As part of a program to study the effect of 
glycosylation on the three-dimensional structures of HIV-ImB 
V3 peptide constructs, we have examined the solution structures 
of a 15 residue peptide (RIQRGPGRAFVTIGK, P18ms), 
originally mapped as an epitope recognized by CD8 + D u class 
I MHC-restricted murine cytotoxic T-lymphocytes (CTL), and 
an analogue (P18mB-g), O-glycosylated with an t~-galactosa- 
mine on Thr-12, using NMR, circular dichroism and molecular 
modeling methods. Our studies show that the peptides sample 
mainly random conformations in aqueous olution near 25°C and 
become more ordered by the addition of trifluoroethanol. Upon 
decreasing the temperature to 5°C, a reverse turn is formed 
around the immunodominant tip (GS-RS). Glycosylation on T Iz 
'tightens' the turn slightly as suggested by NOE and CD 
analysis. In addition, the sugar has a defined conformation with 
respect to the peptide backbone and influences the local peptide 
conformation. These data suggest hat simple glycosylation may 
influence the conformational equilibrium of a V3 peptide which 
contains a domain critical for antibody recognition and virus 
neutralization. We also show that the ability of cytotoxic T- 
lymphocytes (CTL) to lyse tumor cells presenting P18ttm was 
completely abrogated by threonine glycosylation. 
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1. Introduction 
The envelope glycoprotein (gpl20) of human immunodefi- 
ciency virus type 1 (HIV-1) is the primary target of the host 
immune response upon viral infection [1]. The principal neu- 
tralizing determinant (PND) has been mapped to the third 
variable region [2~,] (V3) of the intact protein to which highly 
effective neutralizing antibodies have been raised [5,6]. How- 
ever, the search for effective immunotherapies (vaccines) de- 
rived from this region of the protein have been hampered by 
the lack of cross reactivity and viable efficacy of peptide con- 
structs across different viral strains [7,8]. In addition, immu- 
nization with gpl20 subunit vaccines eem to elicit antibodies 
which neutralize laboratory-adapted isolates but are ineffec- 
tive against primary HIV-1 strains [9]. This is due in part to 
the highly variable nature of the PND sequence between dif- 
ferent isolates and the fact that V3, or other more conserved 
epitopes may be presented ifferently in vivo as compared 
with laboratory-adapted isolates. Hence, the discovery of 
more broadly neutralizing epitopes or a combination of ther- 
apeutically useful regimens i  a timely concern. 
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A second structural class of potentially neutralizing targets 
for immune intervention is the carbohydrate r pertoire cova- 
lently attached to gpl20. The structure and function of these 
glycan chains have now been studied extensively ([10] and 
references cited therein), however, the absolute roles of the 
many sugar chains are still under debate [11]. It has been 
shown that removal of N-linked glycans from gpl20 impairs 
binding of the protein to CD4 + cells [12]. Infectivity is also 
decreased when virus is grown in the presence of inhibitors of 
N-linked glycoprocessing [13]. In addition, synthesis of gpl20 
in the presence of deoxynorjirimicin affects the functional 
antigenicity of the V3 loop [14,15]. Recently, the presence of 
O-linked oligosaccharides on gpl20 has been unequivocally 
determined [16]. Hansen et al. [17] have studied a panel of 
monoclonal antibodies (MABs) specific for carbohydrate 
structures and found several to inhibit virus infection in vitro. 
In particular, those MABs directed to structures uch as Tn 
(c~-GalNAc-Ser/Thr), sialosyl-Tn (sialic acid-c~-2,6-GalNAc- 
Ser/Thr), and Lewis Y antigen (difucosylated lactosamine) 
blocked infection by cell-free virus of several T-cell lines while 
also reducing syncytium formation [17]. This raises the possi- 
bility that carbohydrate structures on gpl20 might constitute 
a novel immunogenic target for the generation of neutralizing 
antibodies. Since antibodies to both peptide and sugar epi- 
topes are effective in neutralizing HIV infection, it follows 
that peptide-carbohydrate conjugates (glycopeptides) may 
prove to be the actual recognition elements on the protein 
which elicit the antibody response in vivo. We have begun a 
program to study the effect that covalently linked carbohy- 
drates have on the three-dimensional conformation of pep- 
tides derived from gpl20. In this report we compared the 
structures of a 15-residue peptide from the HIV-1IIIB V3 
loop and a glycosylated analogue with N-acetylgalactosamine 
(NAG) c~-linked to the threonine four residues to the C-ter- 
minal side of the so-called immunodominant tip [18,19] (se- 
quence -GPGR-) of the loop. As this peptide is also an im- 
munodominant epitope for CTL recognition [20-23], we have 
also tested these peptides for their ability to be recognized by 
class I-MHC molecule-restricted CTL as measured by lysis of 
a tumor cell line incubated with the peptides. 
2. Materials and methods 
2.1. Peptides 
The unglycosylated peptide was purchased from Bachem, CA. The 
glycosylated analogue was prepared by solid-phase ynthesis using the 
Fmoc strategy on an Applied Biosystems peptide synthesizer. Fmoc- 
protected threonine building block containing a 2,3,4-tri-O-acetyl-c~- 
galactosamine was prepared by known methods [24] or was purchased 
from Oxford Glycosystems Inc. Incorporation of this derivatized res- 
idue into the peptide was performed manually by removing the resin 
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and coupling the threonine derivative under Bop activation for 3 h. 
Cleavage of the peptide from the resin was performed with 95% tri- 
fluoroacetic acid (TFA) for 2 h. The precipitated peptide was purified 
by reverse-phase (C18) HPLC using a gradient of acetonitrile/water 
each containing 0.05% TFA. The acetate protecting groups on the 
sugar were removed by brief treatment with freshly prepared 1 M 
NaOMe in methanol at 0°C, The product was repurified by C18 
HPLC affording pure glycosylated peptide as judged by FAB MS 
and NMR spectroscopy. 
2.2. Circular dichroism spectroscopy and FAB mass spectrometry 
CD spectra were recorded at room temperature in the wavelength 
range 19~260 nm, on a Jasco model J-500A/DP501N spectropolari- 
meter, in Hellma QH cells with a pathlength of 1 mm. Peptide con- 
centrations were 200 ~tM in 10 mM phosphate buffer, pH 4.8, TFE or 
TFE/buffer mixtures. Mass spectra were run on a VG-7070-HF in- 
strument using a xenon atom gun and a mixture of DTT/DTE (3:1) in 
20% MeOH as the sample matrix. 
2.3. NMR spectroscopy 
NMR spectroscopy was carried out on a Bruker AMX500 instru- 
ment equipped with an inverse, broadband probe. NMR samples were 
6 mM (PI81IIB) and 10 mM (Pl8Hm-g) in either 90% H20/10% 020 
(DSS as an internal standard) or 100% D20. Spectra in 50, 80, or 95% 
TFE(D2)/H20 were also recorded. The pH values of the aqueous 
samples were adjusted to 4.8 with small amounts of NaOH or HC1 
solutions and were unbuffered. Spectra were collected at 5, 10 and 
25°C under the control of a Eurotherm© variable temperature unit 
with an accuracy of 0.1°C. Two-dimensional spectra (DQF-COSY 
[25], TOCSY [26] and NOESY [27]) were recorded employing stand- 
ard pulse sequences with the number of acquisitions typically set to 
64 for the NOESY and DQF-COSY spectra and 32 64 for the 
TOCSY spectra. Low power presaturation was used to suppress the 
water resonance during the relaxation delay and the mixing period of 
the NOESY experiments. In general, spectra were recorded with 2K 
complex data points in F2 for each of 480-512 tl increments with a 
sweep width of 5050 Hz in each dimension. TOCSY spectra were 
recorded with an isotropic mixing time of 70 ms and trim pulses of 
2.5 ms immediately before and after the spin lock period. NOESY 
spectra were acquired with mixing times of 200 and 400 ms (PI8InB), 
or 400 and 500 ms (P18lnB-g). The 400 ms NOESY experiments were 
used for integration of peak volumes to generate interproton distance 
constraints. The NOEs were classified into five groups of very strong, 
strong, medium, oweak and very weak (upper bounds set to 2.5, 3.0, 
3.5, 4.0 and 5.0 A), respectively. The lower bound limit was set to 1.9 
A. The temperature coefficients of the amide protons were studied by 
collecting TOCSY spectra at seven different emperatures between 5 
and 35°C in 5 degree increments and are reported in ppb/K. All 
spectra were processed with UXNMR on an X32 computer or with 
NMRCOMPASS (Molecular Simulations Inc.) after transfer to a Sil- 
icon Graphics Indigo workstation. The data were zero-filled to 1024 
points in F1 prior to Fourier transform, multiplied by a shifted (45 
60 °) sine function and baseline corrected with a polynomial of order 
5. 
2.4. Molecular modeling and structure calculations 
Molecular modeling were performed with the CHARMm 23 [28] 
force field under the auspices of the QUANTA package (version 4.1) 
for structure generation and graphics display on a Silicon Graphics 
Indigo workstation. Models were constructed with the sequence 
builder facility in QUANTA.  The carbohydrate parameters were tak- 
en from the POLYSACCHARIDE.RTF  residue topology file and 
linked to the threonine hydroxyl by a PATCH command in 
CHARMm.  Energy minimizations were performed with the Adopted 
Basis Newton Raphson (ABNR) algorithm. A series of starting struc- 
tures generated by a minimization-dynamics-minimization protocol 
were submitted to distance geometry-simulated annealing using X- 
PLOR [29] with an added potential which accounted for the distance 
restraints generated from the NOE results. 20 structures with the few- 
est distance violations and lowest energies were chosen for additional 
restrained annealing with CHARMm.  The starting structures were 
heated from 0 to 1000 K (10 ps) and slowly cooled over 70 ps (10 
ps/100 K) to 300 K and simulated for 50 ps at this temperature while 
increasing the force constant of the NOE restraints during the cooling 
Table 1 
1H resonance assignments for the PI8II1B and Pl8mB-g in water at pH 4.8 
Residue NH Cc~H C]3H CyH Others 
Arg-1 4.051 (0.02) ~ 
Ile-2 8.804 4.170 
Gin-3 8.799 4.368 
Arg-4 8.668 4.387 
Gly-5 8.520 (-0.016) 4.150, 4.051 
Pro-6 4.447 
Gly-7 8.642 3.933 
Arg-8 8.305 4.289 (-0.023) 
Ala-9 8.431 4.269 (-0.024) 
Phe-10 8.342 4.644 (-0.052) 
1.906 1.617 8CH2 3.209 
(0.02, -0.036) NH 7.272 
1.799 1.490, 1.186 "/CHa 0.870 
8CH3 0.850 
2.055 (-0.028), 2.332 
1.957 
1.641 (-0.027) 8CH2 3.162 
NH 7.242 
2.012, 1.971 8CH2 3.640 
1.779, 1.700 1.561 riCH2 3.160 
NH 7.217 
1.285 
3.103 (-0.032) 
3.004 
Val- l l  8.214 (-0.044) 4.249 (-0.135) 1.996 (-0.034) 0.909 (-0.034) 
Thr-12 8.737 (-0.307) 4.565 (--0.255) 4.249 (-0.157) 1.265 (-0.064) 
Ile-13 8.448 4.170 1.838 1.490, 1.206 
(-0.027) 
Gly-14 8.596 (0.052) 4.012 (-0.093), 3.795 (0.124) 
Lys-15 8.152 (-0.153) 4.170 1.818 1.403 (-0.050) 
GalNAc IH 4.802 2H 4.081 3H 3.854 4H 3.933 
2,6H 7.233 
3,5H 7.339 
4H 7.287 
~CHs 0.949 
8CHa 0.850 
~iCH2 1.693 
cCH2 2.984 
ENHa + 7.597 
5H 4.012 
6CH2 3.746 
NH 7.873 
CHa 2.016 
(-0.026) 
(-0.052) 
(--0.022) 
~Values in parentheses are the differences in chemical shift caused by glycosylation of P18mB tO P18mB-g. 
Negative values refer to upfield shifts. 
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Fig. 1. Circular dichroism spectra of (A) Pl8nm and (B) Pl8InB-g in water and TFE mixtures. 
260 
period. An additional 50 structures were collected from this step and 
energy minimized. The procedure was repeated to obtain several final 
conformers which agreed well with the experimental data. 
2.5. CTL assay 
The assay and generation of the CTL line utilized here have been 
previously described [30]. Briefly, target cells (1 × 10 rl) were labeled 
with 200 p.Ci of Na2'~lCrO4 in 200 gl complete medium for 2 h at 
37°C. Where appropriate, target cells were pulsed with 1 gM peptides 
during labeling (a near-saturating concentration). Cells were then 
washed and added to 96-well plates (2000/well) along with varying 
amounts of effector cells. After 4 h, supernatants were harvested 
and counted in an Isomedic gamma counter (ICN). The mean of 
triplicate samples and percent of SlCr release were calculated. 
3. Results and discussion 
The glycopeptide was prepared by solid-phase methods and 
purified by HPLC. Yields of purified product were greater 
than 70%. The molecular mass of the synthetic glycopeptide 
was confirmed by positive ion FAB mass spectrometry. The 
circular dichroism spectra of P18mn and P18mB-g in phos- 
phate buffer, 50% TFE and 100% TFE are shown in Fig. 1. 
Both peptides display basically random conformations in 
phosphate buffer (pH 4.8). As the concentration of TFE is 
increased, the peptides become more structured as shown by 
the deviation in the curves to a more positive ellipticity. Slight 
differences are noticeable between the spectra of the peptide 
(Fig. 1A) and the glycopeptide (Fig. 1B). In buffer solution 
the spectra of both samples are similar with the exception of 
an additional ellipticity at 232 nm in the glycosylated ana- 
logue. This region of the spectrum indicates the presence of 
a bend or turn-type motif [31]. As the lipophilic character of 
the solvent is increased, this shoulder is consistently larger in 
the glycosylated analogue. 
The ~H-NMR spectra of P18InB and P18mB-g were re- 
corded at several temperatures but the structurally useful 
data were obtained at 5-10°C since, for small linear peptides, 
rapid sampling of conformational substates i reduced at low- 
er temperature. All resonances including the carbohydrate 
protons for P18um-g were completely assigned using standard 
methods [32]. A comparison of the chemical shifts of both 
peptides is shown in Table 1. Glycosylation causes a notice- 
able shift in the 8 values only for protons in close proximity to 
the glycosylated residue (T12). Backbone three-bond proton- 
proton coupling constants 3JnN,a~t measured from the resolu- 
tion-enhanced, one-dimensional spectra t 5°C revealed values 
in the intermediate range (6--7.8 Hz) for both peptides sug- 
gesting an equilibrium of several conformations even at this 
low temperature. This trend was further supported by the 
temperature coefficients of the amide protons determined by 
a series of TOCSY spectra acquired at seven different em- 
peratures. The temperature coefficient values for P18nm 
spanned from 6.5 to 10.0 ppb/K whereas Pl8mB-g values 
were slightly higher (7.5 13.0 ppb/K). These data indicated 
that no intramolecular hydrogen bonds normally found in 
regions of defined secondary structure were evident for either 
peptide. However, it should be noted that the coefficients for 
R ~ and V 11 in P18nlB (7.3 and 6.5) and in P18m~-g (7.6 and 
7.5) were lower than those for the remaining residues which 
may indicate that, under the experimental conditions, these 
residues may participate in forming a more defined structural 
unit than other segments of the peptide. 
The 2D NOESY spectra for each peptide were collected by 
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Fig. 2. Comparison of the NH-Hct regions of the NOESY spectra 
of PI8mR (A) and P18mB-g (B). Correlations which describe the 
turn around G 5 R a and that reveal interactions of the NAG-NH 
with the backbone are labeled. 
varying temperature, mixing time and solvent composition. 
The expanded fingerprint regions from the NOESY spectra 
of both peptides are compared in Fig. 2. Intraresidue 
d,~a(i,i) and sequential dNN(i,i+l) and d~N(i,i+l) correlations 
were observed for more than 70% of the residues in both 
peptides. A schematic diagram of the magnitude of the 
NOE intensities is shown in Fig. 3. The figure indicates that 
both P18m~ and P18nm-g spectra present weak daN(i,i+2) 
Table 2 
Peptide-N-acetylgalactosamine (NAG) NOEs from P18IIIB-g 
NAG H Peptide H Intensity (calculated 
distance) 
H1 T ]2 NH very weak (3.84) 
113 NH weak (3.02) 
G 14 NH very weak (3.75) 
T 12 CHa medium (4.2) 
T a2 ~H very weak (4.02) 
T z2 ~H very strong (2.2) 
H3 T 12 NH very weak (3.4) 
H5 T 12 CH3 strong (3.29) 
NH T 12 NH strong (2.75) 
T 12 ~H very weak (4.6) 
T 12 [3H medium (3.95) 
T 12 CH3 very weak (5.07) 
-COCH3 G 14 NH strong (3.87) 
correlations between p6 and R 8 along with strong dNN(i,i+l) 
(G 7 and R s) and dNa(i,i+l) (p6 and G 7) peaks which suggest a 
type-II 13 turn is formed in the -GPGR- segment. A very weak 
NOE interaction between the p6 8H and the G 7 NH indicates 
that a small population of a [3-I type turn is also present in the 
conformational equilibrium. The correlations which describe 
the turn around -GPGR-  are absent for P18mB at 10°C where 
they remain visible in the glycosylated analogue. They do 
appear, however, in the P18IIIB spectra at lower temperatures. 
A reverse ~-turn is therefore observed in both peptides, 
although this feature is present in a higher proportion of 
the conformational ensemble sampled by P18iim-g. These 
data indicate that in the presence of the sugar this peptide 
tends toward a more compact structure by tightening the in- 
herent turn centered around -GPGR-. NMR spectra of 
P18mB-g were also recorded in different mixtures of water/ 
TFE. At 80% TFE, stronger dNN(i,i+l) peaks and additional 
dcLN(i,i+2) peaks (i.e. A9/V 1l, I13/K 15 and P6/RS) were ob- 
served. At 95% TFE, the characteristic peaks which define a 
turn around -GPGR-  are more intense under the same con- 
ditions, indicating a higher percentage or a tightening of this 
bend in the structure occurs under lipophilic conditions. The 
distance data for the remaining backbone in TFE solutions 
partially resemble a nascent helical form due to strong 
dNN(i,i+l) and weak daN(i,i+2) NOEs but no long range 
d~N(i,i+3) or dc~p(i,i+3) NOEs were observed. Our data agree 
with several previous NMR studies [33 35,19] and a crystal 
structure of a V3 peptide in the presence of an antibody [36] 
which have described structural elements present in various 
V3 loop peptides, in particular the highly conserved [~-turn 
around the -GPG(X)- segment. 
Several NOEs between the sugar and the peptide backbone 
were observed as outlined in Table 2. A strong NOE between 
the T ]2 NH and the NAG NH was detected along with a very 
strong NOE between the T 12 ~H and NAG HI.  In addition, a 
moderate NOE between NAG H1 and T 12 "~H3 along with a 
strong enhancement between the NAG acetyl methyl group 
and the amide proton on G 14 were observed. These NOEs 
serve to define the preferred torsion angle space sampled by 
the glycosidic ~),~ angles (g) is defined as H1-C1-O1-Thr-CI3, 
and tg as C1-OI-(Thr)-C~-H~) [37]. When the inter- and in- 
P18m8 
daN(i,i+l) 
dNN(i,i+l) 
d[3N(i,i+l) 
daN(i,i+2) 
R I  QRGPGRAF VT I  GK  
1 
RI  QRGP GR A F V T* I G K P18m8 -g 
dc~N(i,i+ 1)
dNN(i,i+l) 
d~N(i,i+l) ~ 1 
dccN(i,i+2) 
Fig. 3. Amino acid sequence and diagram of NOE connectivifies of 
P18nm and P18iim-g collected at 278 K. The thickness of the bars 
directly correlates with the strength of the NOE crosspeak. A blank 
circle represents an NOE of unknown intensity due to peak overlap. 
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Fig. 4. (A) Model of the g]ycosy]ated residue T 12 and the relationship of the sugar with the surrounding amino acid sequence based on the 
NOEs in Table 2. The definitions of angles ~ and ~ are shown. (B,C) Representative structures from the molecular dynamics calculations of 
Pl8iim and P18lm~-g, respectively. The depiction in (C) represents he trajectory which best fits the data that derived the model of the segment 
shown in (A). 
traresidue correlations in this portion of the peptide are in- 
cluded (see Fig. 3), a reasonable description of this segment 
may be ascertained. A representation f a model derived from 
these data for the conformation of the NAG with respect o 
the surrounding peptide sequence is shown in Fig. 4A. 
This structural prediction was also borne out in the calcula- 
tions using a simulated annealing-molecular dynamics proto- 
col. Fig. 4B and C depict low energy models derived from the 
structure calculations (as described in Section 2.4) for Pl8mB 
and P181HB-g, respectively. Not surprisingly, the calculations 
yielded several families of conformations for both peptides 
due to the paucity of interresidue r straints and the inherent 
flexibility for peptides of this size. However, a reasonably 
defined conformation was found for the -GPGR- segment as 
demonstrated by the RMSD values in this region. The entire 
backbone RMSD was 3.7 A for P18IHB but only 0.9 A for the 
residues GS-R s. Glycosylation of T lz not only decreased the 
RMSD value of the backbone atoms to 2.7 A, but also de- 
creased the value for the GS-R 8 segment from 0.9 to 0.6 A. In 
addition, the RMSD value for residues V~1-I13 was 1.0 A for 
P18IIIB and 0.4 A for P18mu-g calculated for all heavy atoms 
(excluding the NAG atoms) in this segment. A survey of the 
best-fit calculated structures suggested the optimum ranges for 
the ~ and gl glycosidic torsions were between --53 and 25 °, 
and -4  and 40 °, respectively. Therefore, although the pep- 
tides sample several different conformers even at low tempera- 
ture, the presence of the sugar imparts additional structural 
integrity to the residues immediately flanking the glycosylated 
amino acid. In addition, the reverse turn encompassing - 
GPGR- is populated to a slightly higher extent for P181HB-g 
than in P18InB. The explanation for this phenomenon is not 
immediately evident. Stabilization of a [3-turn in the immedi- 
ate vicinity of the glycosylated residue has been documented 
for N- [38] and O-linked [39] glycopeptides. However, up- 
stream effects such as the one described here are not as com- 
mon [40]. It is possible the local restriction on the conforma- 
tion near the sugar transmits an effect to distant, defined 
structural elements in the peptide, such as the [3-turn around 
the highly conserved -GPG- sequence. As shown here, how- 
ever, it is still difficult to firmly establish defined structural 
features on small, linear peptides. The use of longer se- 
quences, higher-order oligosaccharides and/or additional mo- 
lecular constraints may advance this conceptual approach of 
structural 'tuning' via glycosylation. A very recent NMR 
study [41] showed that the -GPG(X)-[3-turn was conserved 
in peptides with a [3-glucosamine covalently attached to N 306 
near the N-terminal side of different V3 loop sequences. 
The P18IIIB sequence has been shown to contain an epitope 
recognized by CD8 + D d class I MHC-restricted murine CTL 
[20]. These CTL effectively lyse a target D d positive cell line 
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the murine class I molecule D d recognize target cells pulsed with 
1 gM PI8IHF~ (A) but not 1 laM Pl8mB-g (O). Target cells without 
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positive mastocytoma cetl line P815 (see Section 2). 
either expressing HIV-1IIIB gpl60 endogenously or pulsed 
with PI8IHB. It was later determined [4244] that the mini- 
mum sequence necessary is actually a 10-mer peptide 
RGPGRAFVT I .  The ability of PI8IIIB-g to sensitize Dd-bear - 
ing target cells for lysis by these CTL specific for this 10-mer 
sequence was tested in a 51Cr release assay. Fig. 5 shows that 
PISIIIB pulsed targets are almost completely killed at high 
effector/target cell ratios, whereas P18IIIB-g pulsed targets 
are not killed above background. This is most probably due 
to undesired steric effects where the sugar essentially destroys 
the high affinity binding interaction between the glycopeptide 
and either MHC- I  molecules or the T-cell receptor on the 
target cells. Alternatively, the modified peptide may not pre- 
sent conformations in the vicinity of the carbohydrate which 
are recognized by its binding partners. Since previous data 
indicated [21 23,44] that V 11 was critical for P18IIIB binding 
to the target T-cell receptor, and that Y 12 contacted the T-cell 
receptor as well, this binding event is more likely to be ad- 
versely effected by T 12 glycosylation. 
In conclusion, the solution conformation of a 15-residue 
peptide, O-glycosylated at Thr-12 with an c~-linked galactosa- 
mine, was shown to be quite different from the unglycosylated 
sequence. The highly conserved turn moti f  (-GPGR-), as de- 
termined from structural studies on other V3 peptides, is pres- 
ent in both peptides at low temperature and sampled to a 
higher extent in the glycosylated analogue. The ability of 
this peptide to sensitize tumor targets for specific MHC-I-re- 
stricted T-cell lysis, was abolished upon T 12 glycosylation. 
Studies on the structure-activity relationships of other glyco- 
sylated gpl20 peptides with respect to their immunogenicity 
are in progress. 
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